This investment trust buys small companies, especially early-stage firms at the cutting edge of technology. Last year it returned nearly 30%, far beating the market, but it also widened its losses and pushed its stake in unlisted companies above the allowed limit, with SpaceX alone making up about a sixth of the fund. Now a big shareholder wants to replace the whole board, with a vote due in January. For ordinary investors, the story shows how strong returns can come with concentration and governance risks – and why it matters to look beyond the headline number.
Edinburgh Worldwide's Path for Growth strategy is beginning to show results, but excessive private company exposure and Saba's second campaign make the future uncertain (Cautious).
The letter states that Edinburgh Worldwide is positioned as a global small-cap specialist, pursuing long-term capital appreciation through early-stage investments in listed and private companies at the forefront of technological innovation. This chapter contains no annual performance or position-change data; it focuses on the strategy's logic and a self-explanation of the investment philosophy. The discussion below is therefore relayed on two levels: "opportunity assessment" and "investment philosophy."
The company believes it is in a period of profound transformation: foundational technologies such as processing power, genomic sequencing, and battery storage — after decades of exponential cost declines and capability improvements — are converging and expanding the innovation frontier. The explosion of data collection, connected devices, and renewable energy will accelerate change. The next decade will be shaped by artificial intelligence, a deeper understanding of biology, and electrification, while space exploration and quantum computing move from theory to operations. The companies that best harness these technologies will reshape society and become assets of strategic importance.
Small, progressive companies offer a distinct route to participating in technological change compared with large, slow-moving incumbents: free from the "innovator's dilemma," the need to protect existing businesses, or conflicting internal priorities, they can design business models from a blank sheet; the internet, cloud computing, and digital networks allow them to reach customers or scale operations at unprecedented speed, eroding the traditional advantages of large companies. The letter notes that market attention to such opportunities has fluctuated over the past three years, but the opportunity itself remains enormous.
The letter crystallizes the core of its methodology in a single sentence: "Essentially, it is not about being right with the median investment but about 'how right' the Managers are with the top-performing holdings." (In other words, what matters is not being correct on the median investment, but how correct the Managers are on the best-performing holdings.) Readers should note that this chapter was written by the company itself; its optimistic account of technological change and small-company opportunities reflects the perspective of the invested party, not an independent assessment.
The Path for Growth strategy is not merely a slogan — its execution is clearly visible in the portfolio's actual changes. The number of holdings fell from 110 in 2023 to 100 in 2024, already below the 110-stock band previously maintained for a long period and moving toward the new target range of 60-100 holdings. More importantly, the portfolio's "financial resilience composition" has undergone a systematic shift:
| Financial Resilience Category | 2023 Weight | 2024 Weight | 2025 Weight | Trend Notes |
|---|---|---|---|---|
| Fledgling (no positive gross margin) | 4.1% | 3.1% | 1.6% | Sharply reduced; high-risk early-stage names significantly fewer |
| Initial Commercialisation (positive gross margin) | 25.2% | 16.0% | 14.6% | Steady decline; reduces early-commercialisation uncertainty |
| De-Risking (FCF margin -20% to 0%) | 30.8% | 16.2% | 17.7% | Stabilizes after marked contraction |
| Execution (positive FCF) | 15.3% | 26.8% | 25.1% | Roughly doubled and remains elevated |
| Proven Return (positive FCF + EPS) | 24.6% | 37.9% | 41.0% | Rises from about a quarter to over 40%; becomes the largest category |
This shift is direct evidence of "increased resilience and focus": the portfolio has tilted from the early growth stage toward a more mature, revenue-generating stage. At the same time, sector allocation reflects the same logic — healthcare fell from 36.2% to 26.0%, while information technology and industrials, two sectors with greater cash-flow certainty, rose to 30.4% and 28.7%, respectively. The "sell discipline" emphasized by the Board is now visible in the data: rather than paying for high-valuation stories, the portfolio is rotating toward companies with proven business models.
Unlisted investments have always been a differentiating advantage for Edinburgh Worldwide. During the period, their weight fell from 25.3% to 22.0%, which appeared to represent tightening — but the subsequent revaluation of SpaceX changed the picture entirely:
This event has a twofold effect. On one hand, it significantly boosts NAV, demonstrating the Managers' ability to identify "disruptive enterprises" in the private market — precisely the scarce value that distinguishes the company from an ordinary small-cap trust. On the other hand, it breaches the 25% unlisted investment cap authorized by Shareholders. Although the policy permits holding above the cap while prohibiting new investments, the situation creates an urgent task for the Managers and the Board: they need to actively seek exits or liquidity events in the future to create new investment room. The SpaceX mark-up itself also serves as a "stress test"; if similar revaluations occur in the future, private company exposure could rise further, and the Board must remain vigilant.
During the period, the company reduced its investment leverage substantially from +10.9% at the end of 2024 to +2.4% — a very significant strategic shift. Against a backdrop of a 30.2% rise in the share price, the voluntary deleveraging signals management's caution regarding market volatility and private company exposure, rather than pessimism about the future. Two credit facilities (£100m and £36m) mature in mid-2026, and renewal arrangements are already planned, indicating that the company retains the flexibility to re-lever in the future.
Meanwhile, the buyback program continued: during the period, the company repurchased 24,442,616 shares for £42.6m, equivalent to 6.6% of the share capital outstanding at the start of the period. Although the discount narrowed only modestly, from 7.6% to 7.2%, the effect was limited; but the buyback itself sent a positive signal to the market that the Board is responding to the discount. It is worth noting that there is a link between buybacks and private company exposure: in deciding on buybacks, the Board is "mindful of" the private company weight and leverage levels. This effectively builds a layer of capital cushion — when low-liquidity private companies account for too high a share of NAV, buybacks can partly offset the potential risk of NAV inflation.
In February 2025, the company's largest Shareholder attempted to replace the entire Board and proposed a different future plan, but met with overwhelming opposition from shareholders. That outcome validated that the Path for Growth strategy had won broad support at the time. However, the situation deteriorated sharply thereafter: that shareholder increased its stake further and launched another Requisitioned General Meeting, scheduled for January 20, 2026. In the annual report, the Board directly called on all shareholders to VOTE AGAINST all resolutions, emphasizing that protecting the company's independence is to "preserve access to some of the world's most exciting and transformative public and private businesses."
This creates a highly charged narrative: performance had just demonstrated that the strategy works (NAV growth of 29.7%, far exceeding the index's 12.8%), the SpaceX revaluation provided a powerful catalyst, yet external pressure escalated nonetheless. In the annual report, the Board acknowledged "differing perspectives and lack of clear objectives" on the part of the largest shareholder, implying that the latter had not proposed a plan superior to the existing strategy. At this point, the NAV uplift from the SpaceX revaluation effectively strengthens the Board's bargaining position — shareholders can see that the existing strategy's distinctive capability in private investing has produced real returns, and replacing the Board could mean losing that capability.
Taken together, Path for Growth's first-year execution data is solid: portfolio resilience improved markedly, returns outperformed the index by nearly 17 percentage points, unlisted investments contributed excess returns, and leverage remained within a safe margin. But risks are also accumulating: private company exposure exceeds the cap, SpaceX alone is concentrated at 15.9%, and the upcoming general meeting brings uncertainty. These factors mean that whether "performance momentum" can be sustained in the next phase (i.e., fiscal 2026) will be decisive in determining the direction of this governance contest.
On December 2, the company announced a proposed merger with Baillie Gifford US Growth Trust plc; on December 3, Saba launched its second campaign — leaving virtually no time window for a considered reaction. The more reasonable interpretation is that Saba had long since prepared its campaign plan; the merger announcement was merely the trigger it was waiting for. Saba's opposition to the merger is not a rejection of the merger's intrinsic value, but rather a reluctance to see the company expand in scale and strengthen its independent position through the merger, thereby reducing the likelihood of Saba's subsequently gaining control. If the merger were completed, Saba's 30% stake would be diluted, and the new board structure would be more complex, raising both the cost and difficulty of any takeover.
Saba holds 30% of the company's issued share capital. Under the UK Companies Act framework, this means it is sufficient to block any special resolution requiring approval from 75% of shareholders, including amendments to the articles, merger plans, and compulsory buybacks. What is truly noteworthy is that the company did not attempt to advance the merger around Saba — for example, through a court-sanctioned scheme of arrangement or other legal routes. This indicates that the Board concluded Saba's opposition was an insurmountable obstacle to the merger, not merely an opposing party with whom one could negotiate. This indirectly confirms that Saba has secured structural influence in the company's governance, well beyond the level of an ordinary major shareholder.
| Dimension | First Campaign (roughly a year ago) | Second Campaign (December 2025) |
|---|---|---|
| Explicit demands | Replace the Board, remove the investment managers, and transfer investment management to Saba | Only demands replacing all independent directors; silent on follow-up plans |
| Communication strategy | Publicly claimed that changing the company's distinctive strategy was in shareholders' interests | Has not disclosed what comes after the merger is vetoed: a specific alternative strategy or operating plan |
| Stake size | Did not reach the key veto threshold | 30%, enough to unilaterally block major special resolutions |
| Timing | Early stage of the company's strategy transformation | Just as the first full strategy year ended and performance was beginning to improve |
Although the first campaign's demands were aggressive, they were at least clear in purpose — Saba wanted to become the investment manager. The second campaign, by contrast, presents a kind of "destructive silence": it demands control of the Board but declines to say what it would do once in control. This ambiguity is dangerous for rational long-term shareholders, because it turns the company's future into an unpredictable lottery ticket.
A merger with Baillie Gifford US Growth Trust could produce multiple positive effects: the combined fund's assets would be expected to exceed £1 billion, with significant improvements in secondary-market liquidity, index inclusion weight, and institutional investors' allocation thresholds. Small-cap growth strategies often face the problem of elevated fee ratios due to insufficient scale — the company's current ongoing charges ratio is 0.85%, up from 0.76% in the previous fiscal year — while the cost-spreading effect of a merger could be expected to reduce the rate. Moreover, a merger of two trusts managed by the same investment manager has a natural basis for rationalization in both investment-strategy synergies and operating-cost reduction.
| Metric | Before Merger (Current) | After Merger (Estimated) |
|---|---|---|
| Total assets (before deducting borrowings) | £847.0m | Expected to exceed £1bn |
| Ongoing charges ratio | 0.85% | Could fall below 0.75% |
| Index inclusion | Potentially constrained by size thresholds | Easier entry into major small-cap indices |
| Shareholder structure | Saba at 30%, highly concentrated | Saba's stake diluted, more diversified |
Saba's veto has pressed pause on these potential benefits. But what deserves more attention is this: in vetoing the merger, Saba — a shareholder holding 30% — has not offered an alternative value-enhancement plan. If Saba believed the merger destroyed value, it should have presented its preferred alternative — for example, splitting up the portfolio, distributing unlisted assets, or replacing the investment manager with one having a better track record. Yet the second campaign's statement does not mention any of these. Two possibilities lie behind this: one, Saba has a genuine asset-management plan but cannot disclose it in advance; two, Saba's strategic focus is on capturing management fees and control, not on adding value to the company's fundamentals. Either way, for minority shareholders this means uncertainty risk.
The most telling data point is not the 29.7% rise in NAV, but the 58.6% widening of the income loss — from a loss per share of 0.70p to 1.11p. This is not a modest deterioration; it is an income-statement deterioration of nearly 60%.
| Return Component | 2025 | 2024 | Change |
|---|---|---|---|
| Capital return | 49.96p | 19.48p | +156.5% |
| Income | (1.11p) | (0.70p) | -58.6% |
| Total return | 48.85p | 18.78p | +160.1% |
The sharp increase in capital returns indicates that valuation re-ratings of high-growth companies in the portfolio contributed significantly; the widening income loss, meanwhile, reflects that more companies in the portfolio are in the "burn cash for growth" stage — these companies consume more cash than they generate in revenue, but they are precisely the source of potential high future returns. This divergence is a defining characteristic of the Path for Growth strategy: trading current income for long-term capital appreciation. Saba could precisely use this data point to attack the strategy's sustainability — if the company cannot accumulate revenue reserves over the long term, its future dividend capacity weakens, making it unattractive to income-dependent shareholder groups.
The increase from 0.76% to 0.85% occurred during a sensitive period when the company was facing a hostile takeover. The increase stems from factors such as performance fees arising from total asset growth, but in Saba's framing, this figure would be packaged as "management increasing the cost burden even in a time of crisis." An even more unfavorable combination: widening income losses, rising charges, and zero dividends. Taken together, these three items provide citable data support for Saba's characterization of the company as "unfriendly to shareholders."
| Discount/Premium Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Average discount | (7.2%) | (7.6%) |
| Highest premium | 4.0% | (4.4%) |
| Lowest discount | (11.3%) | (17.7%) |
During the year, the discount narrowed from -11.3% to a premium of 4.0%, a range spanning more than 15 percentage points. This extreme volatility sends two signals. First, the market's attitude toward the company's strategy transformation swung violently, from deep skepticism to marked approval. Second, share-price volatility was far greater than NAV volatility, indicating that capital flows and market sentiment play an outsized role in a trust of this size — precisely the soil that emboldens Saba to launch aggressive campaigns: a 30% stake is enough to create considerable disruption in a market with limited liquidity.
Over the 11 years and 9 months from the widening of the investment policy on January 31, 2014, to October 31, 2025:
| Metric | Total Return |
|---|---|
| NAV total return | 153.9% |
| Share price total return | 151.3% |
| S&P Global Small Cap Index (in GBP) | 205.8% |
| Excess gap versus the index | -51.9 percentage points |
This comparative data is Saba's most powerful attacking argument. Over the past nearly twelve years, an investor who placed the same amount of money in an index fund would have ended up with returns roughly one-third higher than by investing in this trust. Even with the strong fiscal 2025 performance, only part of the long-term relative shortfall has been recovered.
However, this data requires a threefold analysis. First, the index is an all-market small-cap index covering a large number of value and cyclical companies; it is not in the same style dimension as the trust's focus on "disruptive growth companies." Style differences alone can explain a considerable portion of the divergence. Second, the trust's NAV growth of 153.9% is net of fees, whereas the index return excludes any management charges; if fees were factored in, the active manager's actual excess return gap would narrow, but it would still be negative. Third, this long-term underperformance occurred precisely before the Path for Growth strategy was launched — whether the previous strategy had systemic problems is the real question for historical assessment.
The announcement of Mungo Wilson's retirement appeared after Saba launched its campaign. On the surface, this is merely a natural succession at the end of a nine-year term; but placed in the context of the company facing an external takeover threat, its impact is significantly amplified:
The Board's composition has become more fragile both in quantity and quality. This governance risk resonates at a dangerous frequency with the Saba campaign.
The Managers regard AI as the start of a "multi-decade reset in computing," and have explicitly shifted the narrative from the "LLM boom" to "the expansion of computing infrastructure plus the explosion of use cases." This framework explains the logic behind the portfolio's heavy positions in AI chips, data centers, quantum computing, and technology-innovation companies oriented toward national security and corporate resilience. This narrative has macro-level persuasiveness, but it is insufficient to dissolve micro-level valuation risk.
In 2025, the market has already priced the AI sector quite fully — the US hyperscaler capital-expenditure race and the massive fundraising by LLM builders such as OpenAI and Anthropic are all crowding out the return space for the next several years. When a small-cap growth fund holds the supply-chain or downstream-application companies serving these players, its performance is highly dependent on the continued expansion of the entire AI ecosystem. If evidence emerges at any stage that AI investment return cycles are longer than expected, the portfolio's drawdown will far exceed that of a broad-based index.
The Managers' mention of "returns from companies related to national resilience and adaptability" indicates that the portfolio has partly shifted from a pure growth theme toward geopolitical-hedge type holdings. This adjustment reflects less the alpha capability of active stock selection than the fund being led by the macro environment — moving from pure growth to defensive growth is, in essence, a compromise under current political uncertainty. Saba could readily interpret this strategic vacillation as "lacking a stable investment philosophy."
| Date | Event |
|---|---|
| December 3, 2025 | Saba launches its campaign |
| December 2, 2025 | Merger proposal announced only one day earlier |
| January 12, 2026 | Voting deadline on some platforms |
| January 17, 2026, 12:00 | Final voting deadline |
| April 2026 | AGM to be held |
From Saba's campaign launch to the earliest voting deadline is only 40 days. From the merger announcement to the voting deadline is only 46 days. For retail shareholders, the time pressure is substantial: in this short window, they must understand Saba's true intentions, assess the differences between the two campaigns, evaluate the potential impact of the blocked merger, and complete the voting process — especially via platforms requiring responses by mail. The Board's choice to issue the Chair's statement on January 12 (the day some platforms' voting closes) shows that it, too, is using the timeline for a final mobilization. This is the last lever the company can pull on the time dimension.
The defining feature of Saba's second campaign is the opacity of its objectives. The first round at least displayed the concrete intention of "Saba taking over investment management"; the second round only demands the replacement of the Board — but the path after replacement is a complete blank. Saba has neither publicly presented any management plan for the portfolio nor made any alternative commitment regarding the company's direction after the merger is vetoed. This posture of "control without accountability," combined with its 30% veto position, constitutes a substantive threat to the company's existing shareholders. The choice facing shareholders is no longer "who manages the company," but "whether the company will head in an unknown direction defined privately by a 30% shareholder and entirely invisible to the other 70%."
Although the performance data shows a strong rebound in a single fiscal year, the long-term underperformance versus the index, the widening income loss, and the rising charges all provide ammunition for Saba's narrative. Whether the company can win this governance battle depends not only on the share price over the next three months, but more on whether the Board can present, before the vote, a clear and specific forward plan that stands in sharp contrast to Saba's vague vision — rather than merely repeating the plea to "support us."
The drag from Sweetgreen, Ocado, and RxSight did not originate in the macro environment; rather, they jointly point to two micro-level problems: demand-assessment bias and execution gaps. Sweetgreen maintained brand recognition amid the healthy-fast-food wave, but its store-level economics failed to keep improving under inflationary pressure, and same-store sales growth slowed markedly. Ocado's difficulties are more structural — its B2C grocery delivery faces intense competition in its home market, while its technology-licensing business is long-cycle and high-barrier, meaning the uncertainty of revenue recognition has been re-priced by the market. RxSight's post-operative adjustable intraocular lens has a technological moat, but the recovery in ophthalmic procedure volumes was slower than expected, compounded by rising expense ratios from sales-force expansion, delaying profit delivery.
From a portfolio-management perspective, the commonality among these three holdings is "the story was right, but the timing was wrong." The rigor of the investment framework is shown in this: when the timetable for fundamental validation is repeatedly postponed, and the company itself cannot demonstrate through operating data its ability to adjust, continuing to hold raises opportunity costs — capital becomes locked in low-conviction waiting, while high-conviction opportunities in the AI ecosystem rapidly deliver during the same period. The decisive exit from Sweetgreen, in sharp contrast to the continued additions to Alnylam and SpaceX, embodies the core concept of "competing capital" in the framework: resources tilt toward ideas that realize value fastest.
The new holdings Aspeed, IREN, and Horizon Robotics, on the surface in different tracks, in fact form a complete picture of AI compute power from the physical layer to the application layer. The table below maps their distinct positions in the data-center value chain:
| Company | Core Products/Services | Role in AI Infrastructure | Core Competitive Advantage |
|---|---|---|---|
| Aspeed | BMC (baseboard management controller) | The "nerve endings" of server remote management, monitoring, and fault repair | ~70% global BMC market share; deeply embedded with major server ODMs |
| IREN | Power + land + data-center construction and operation | A "compute real-estate developer" converting scarce energy into programmable compute | Has secured over 2 gigawatts of power resources in Texas; strong construction capability |
| Horizon Robotics | Autonomous-driving/robotics AI chips and software | A "China alternative" for AI vision at the edge | Entered via the domestic ADAS market; integrated software-hardware ecosystem now spilling over into robotics |
Aspeed's value lies not in the process-technology sophistication of its chips themselves, but in its being a direct beneficiary of rising AI server complexity. As GPU clusters scale up, each server's management needs evolve from simple power-on/off to real-time power optimization, fault isolation, and firmware updates; the compute and functional demands on the BMC rise in tandem. Aspeed's near-monopoly position in the BMC market allows it to enjoy both volume and price increases simultaneously: growth in AI server shipments brings new demand, while the ASP of a single BMC rises on enhanced functionality.
IREN's transformation, in turn, validates the logic of "digital demand migration." Its early bitcoin-mining business was essentially general-purpose compute arbitrage using low-cost power; when AI training's marginal willingness to pay for compute far exceeded mining returns, the company reallocated its scarce power resources and data-center expertise to the highest-ROI use case. This "compute arbitrage" strategy is conceptually similar to the chip companies that transitioned from PCs to mobile — the key is not in binding to a specific application, but in securing the generality of the underlying infrastructure. IREN's distinctiveness lies in having locked up energy contracts that others would find difficult to obtain, which constitutes a natural barrier.
Horizon Robotics' long-term narrative extends well beyond autonomous driving itself. Its success in China demonstrates that in the AI chip field, competing purely on compute parameters is not the only path; software-hardware co-optimization combined with local scenarios can equally build competitiveness. Its latest Journey-series chips have secured design wins with multiple domestic brands and are beginning to expand into robotics and industrial vision. This path resembles NVIDIA's "platformization" strategy, but with a greater cost advantage — given China's need for supply-chain security, its market space may be broader than it appears on the surface.
The logic for initiating the Kratos position is similar to that for MP Materials: both are products of geopolitical supply-chain restructuring. But compared with the trade barriers of rare-earth magnets, Kratos taps into a deeper paradigm shift: defense procurement is moving from a small number of platforms pursuing ultimate performance toward cost-affordable, large-scale expendable systems. The Russia-Ukraine conflict has already demonstrated that inventories of expensive precision weapons are consumed far faster than they can be produced, while low-cost autonomous platforms can be replenished quickly.
Kratos's core assets are its accumulated expertise in small turbojet engines, low-observable design, and modular manufacturing. The positioning of its Valkyrie drone as a "loyal wingman" essentially strips out a portion of the missions previously performed by expensive manned fighters (reconnaissance, electronic warfare, even decoys) and forms an expendable extension node. This model will change the operational economics of air force formations. More importantly, Kratos is converting the mature technologies it accumulated in the target-drone field into offensive weapons, with a clear product upgrade path. Compared with large defense prime contractors, it is smaller in scale and faster in decision-making, better suited to the response speed required when new demand erupts.
Guardant Health's position in precision cancer diagnostics is extending from "companion diagnostics" toward "early screening." The greatest value of a blood test lies in lowering the threshold for cancer screening to a non-invasive, radiation-free procedure, thereby expanding the addressable population. Its approved single-cancer colorectal screening is only the first step; once multi-cancer simultaneous detection is achieved by adding methylation markers, the marginal cognitive cost per single test will be amortized. For such companies, the uncertainty lies in the speed of payer-policy adoption and clinical-guideline acceptance; but they can be seen to sit on the same curve as Alnylam — in both cases, once technological validation is complete, commercialization scales in a non-linear leap.
UTI, by contrast, is a textbook "supply-demand mismatch" holding. The US labor market's demand for skilled tradespeople (electricians, welders, medical technicians) continues to outstrip supply, and traditional four-year college degrees cannot fill this gap. UTI's value lies in its deep ties to industry — employers sponsor tuition, training is targeted, and graduate placement rates are extremely high. On the policy front, support for vocational education is one of the rare consensus issues across administrations. The moat of such companies is not technology but the regional ecosystem formed by accreditation systems, campus networks, and employer relationships, which is extremely costly to replicate.
The new investments span, in breadth, semiconductors, new-energy infrastructure, defense electronics, biotechnology, education services, and other fields, but their shared underlying logic all points to areas where, under technological or structural change, supply cannot respond elastically and immediately. The reduction of the portfolio to ~70 holdings is not about lowering coverage, but about ensuring that every holding can be deeply researched and its investment thesis clearly articulated. From exiting negative holdings to building new opportunities, the core of this rotation is "concentrating limited cognitive resources on the most certain structural growth axes of the next five years" — AI-driven reconstruction of compute infrastructure, geopolitically driven supply-chain autonomy, and demographic-driven revolutions in healthcare and education efficiency.
The description of private company valuations in the continuation, superficially an account of process, in fact reveals one of the trust's core competitive strengths — a high-frequency, independent, event-driven pricing mechanism for illiquid assets. This is not merely a compliance requirement; it is infrastructure for investment decision-making.
Looking at the data, in the year ended October 31, 2025, 83% of the private company portfolio was valued more than five times, far exceeding the conventional "once per quarter" baseline. This means that the vast majority of holdings triggered at least one "re-valuation" or "material event" mechanism — including IPO intentions, acquisition approaches, and shifts in comparable company valuations. The result of this high-frequency adjustment: the average valuation movement for private companies was 34.4%, while the average movement in public company security prices was only 8.6%. The gap between the two reveals the high volatility of private company assets, and also means the trust is willing to absorb greater short-term book-value fluctuation in exchange for long-term disruptive growth opportunities.
The independence of the valuation process is also noteworthy: the valuation committee is fully segregated from the investment team; the investment managers are notified only after the final valuation takes effect, and the final results are subject to external audit. This mitigates, to some extent, the moral hazard of "self-praise," and serves as an endorsement of trustworthiness for investors.
| Valuation Dimension | Private Companies | Public Companies |
|---|---|---|
| Average valuation movement (annual) | +34.4% | +8.6% |
| Valuation frequency | 83% of portfolio ≥5 times/year | Daily real-time market pricing |
| Price-discovery mechanism | Quarterly rolling + trigger events | Continuous market trading |
| Independent oversight | Valuation committee + S&P Global + audit | Regulators + market discipline |
Looking at the overall book-value change, the private company portfolio's value edged up from £182.97 million at the start of the period to £186.63 million at the end (+2.0%), but internal activity was intense: sales generated proceeds of £69.19 million while realizing gains of £58.68 million; investment revaluations added £52.10 million and impairments reduced £37.94 million. This shows that the fund is not simply "buy and hold"; rather, it trades frequently amid high volatility — realizing gains when available and cutting losses decisively. This operating style is highly consistent with the Managers' stated "opportunity-cost orientation": when a holding's expected return is no longer attractive, it is replaced even if it has not incurred a loss.
The top-ten holdings list reveals a clear structural shift. Take SpaceX as an example: its valuation fell from £90.07 million to £71.15 million (-21%), while net selling during the year reached £69.11 million — a classic case of "actively reducing positions after high valuations." Alnylam Pharmaceuticals, by contrast, was added to (net purchases of £9.84 million), with its valuation rising 37.7% to become the second-largest holding after SpaceX. PsiQuantum and American Superconductor posted valuation gains of 53.7% and 72.4%, respectively, showing that the fund's early positioning in quantum computing and energy infrastructure is now paying off.
| Company | 2024 Valuation (£k) | 2025 Valuation (£k) | Valuation Change | Net Purchases/Sales During Year (£k) |
|---|---|---|---|---|
| SpaceX | 90,073 | 71,152 | -21.0% | -69,110 |
| Alnylam Pharmaceuticals | 41,779 | 57,547 | +37.7% | +9,834 |
| PsiQuantum | 35,923 | 55,234 | +53.7% | — |
| AeroVironment | 30,325 | 39,629 | +30.6% | +7,396 |
| American Superconductor | 15,886 | 27,373 | +72.4% | +4,983 |
These figures illustrate two points:
1. Being a top holding does not mean "permanently static." SpaceX remains the largest position (8.4% weighting), but the fund decisively trimmed roughly one-third of the position at high share prices, rather than allowing a single name to balloon indefinitely within the portfolio. This discipline of "trimming into strength" is especially rare in growth investing.
2. New-economy hard tech is replacing traditional software/SaaS. Among the 29 positions sold during the year were typical software/biotech names such as Sprout Social, Quanterix, and Blackline. Meanwhile, new additions or increases were concentrated in eVTOL (Ehang), RFID hardware (Impinj), quantum computing (PsiQuantum), defense drones (AeroVironment), and grid technology (AMSC) — a clear style shift from "asset-light digitalization" to "heavy hardware/physical-world automation."
All top ten holdings are U.S. companies (SpaceX, Alnylam, PsiQuantum, AeroVironment, AMSC, Oxford Nanopore, Axon, etc.), with roughly 60% falling into the "deep tech" category. This concentrated geographic and industry exposure means the fund's management holds a strong conviction in the "U.S. innovation ecosystem." From a risk perspective, however, the lack of non-U.S. hedging (e.g., Europe, Asia) could also amplify the portfolio's volatility in response to dollar policy or specific industry cycles.
However, looking at new holdings outside the top ten (such as China's Ehang) sends a signal: the trust is not blindly "betting on America," but rather deploying small positions to capture "unique breakthroughs" globally. Ehang is currently the world's only eVTOL manufacturer approved by regulators for commercial operations—a logic similar to that of PsiQuantum (the only company building quantum computers using silicon photonics) among the top ten holdings. This strategy of "betting on species-level innovation" allows the portfolio to go all-in on very few areas rather than diversifying evenly.
Based on the aggregated data, the trust underwent an evident "major cleanup" in fiscal 2024–2025: it sold 29 investments, trimmed two strongly performing positions, and added exposure to multiple new directions. This level of turnover far exceeds that of a typical long-term growth fund, yet it differs from short-term trading—every move is grounded in a reassessment of "opportunity cost."
The valuation movement data (private companies +34.4%) serves as a reminder that paper returns can far exceed actually realizable cash returns (given the uncertainty around exits from private companies). When evaluating this fund, investors should focus on both the "concentration of unrealized gains" and the "ability to realize them." Private companies currently account for a fairly high share of the portfolio, but through high-frequency valuations and periodic position reductions, the fund is working to maintain liquidity redundancy—the roughly £70 million raised from sales provides ammunition for subsequent investments.
Overall, the sequel paints the trust as: an enterprising investor targeting "the most fundamental technological transformations of the coming decade," anchored by rigorous governance, and willing to correct course amid high volatility. This style may not suit all investors, but its efforts to make private asset pricing more transparent undoubtedly set a reference-worthy example for the industry.
The valuation data for Xometry, Oxford Nanopore Technologies (ONT), Zillow, and Astera Labs in the sequel provides more precise evidence of position adjustments than the narrative descriptions:
| Company | Business Positioning | 2025 Valuation (£'000) | 2024 Valuation (£'000) | Net Purchases/Sales (£'000) | Position Change |
|---|---|---|---|---|---|
| Xometry | Digital manufacturing platform | 22,440 | – | +13,871 | New position, entering top 10 holdings directly |
| Astera Labs | AI connectivity hardware | 14,372 | – | +4,596 | New position |
| ONT | DNA sequencing technology | 21,076 | 21,445 | -1,056 | Slight reduction, valuation broadly flat |
| Zillow | Online real estate platform | 16,263 | 23,601 | -12,002 | Significant reduction of ~31% of position |
The key signal lies in the directional contrast between new positions and reduced positions: Xometry and Astera Labs did not appear in the holdings list in 2024, yet by October 2025 they had already reached 2.6% and 1.7% of total assets, respectively. Despite Zillow's positive absolute return over the period (+21.9%), the fund still chose to actively reduce the position, suggesting the adjustment logic is not simply "chasing winners and dumping losers," but rather an active rebalancing of portfolio structure—shifting capital from platform companies whose valuations have been fully re-rated toward infrastructure-type companies with stronger technological inflection points and larger potential market space.
The twelve-month performance data reveals sharp divergence within the portfolio:
| Return Range | Number of Companies | Representative Companies |
|---|---|---|
| >100% | 4 | QuantumScape (+249.5%), IREN (+248.7%), Astera Labs (+212.8%), American Superconductor (+136.8%) |
| 50%~100% | 11 | Guardant Health (+92.2%), SpaceX (+85.5%), AEHR (+80.7%), etc. |
| 0%~50% | 3 | Xometry (+35.8%), Zillow (+21.9%), ONT (+1.9%) |
| <0% | 2 | Exact Sciences (-8.2%), Twist Bioscience (-20.4%) |
A structural fact worth noting: all four holdings with returns exceeding 100% point to the two themes of energy transition and AI infrastructure. IREN is a combination of data centers and renewable energy; American Superconductor benefits from grid upgrades and military demand; QuantumScape represents the solid-state battery route; and Astera Labs is a core supplier for AI data center interconnectivity. This indicates that excess returns in fiscal 2025 were highly concentrated, with a pronounced "80/20 divergence" within the portfolio.
In contrast, the two negative-return holdings—Exact Sciences and Twist Bioscience—both belong to the genomics/biotech application layer, while Guardant Health, which operates in the same liquid biopsy track, achieved a +92.2% return. This shows that the track is not under uniform pressure; rather, decisive divergence has emerged among companies in terms of technology pathways, commercialization, and clinical validation progress.
In the table, the return data for Xometry, Astera Labs, Guardant Health, and IREN carry the ‡ marker, denoting "part-period returns." This is not merely a technical note; it conveys information on three levels:
First, the fund's positioning timing is highly efficient. Astera Labs and IREN both achieved returns exceeding 200% in less than a full year of holding, indicating that the fund captured the valuation re-rating window for AI infrastructure and energy data centers between late 2024 and 2025.
Second, the ramp-up speed of new positions is extremely fast. Guardant Health went from zero to a 1.6% weight, Astera Labs to 1.7%, and Xometry to 2.6%, all within one year. This reflects the fund's decisiveness in adding to high-conviction opportunities, in sharp contrast to the gradual reduction of legacy positions such as Zillow and Ocado over successive years.
Third, it highlights the portfolio's turnover logic. The largest net purchases in fiscal 2025 (Xometry +£13.9m, IREN +£11.1m) came almost entirely from new directions, while the largest net sales (Zillow -£12.0m, and other legacy positions where share reductions were not disclosed) came from traditional internet and existing holdings. Capital flowed from "proven but slowing-growth" companies to companies "at the early stage of technological inflection with greater non-linear growth potential."
The full List of Investments further shows that the fund's participation in unlisted companies is not a single-round "bet-style investment," but rather employs a continuous position-building architecture across rounds and instruments:
| Company | Instruments Held | Combined Valuation (£'000) | % of Total Assets |
|---|---|---|---|
| PsiQuantum | Series C Preferred + Series D Preferred | 55,234 | 6.5% |
| Shine Technologies | Series C-5 Preferred + Convertible Promissory Note + Convertible Loan Note | 11,031 | 1.3% |
| BillionToOne | Series C Preferred + Series C-1 Preferred | 9,498 | 1.1% |
| Astranis Space Technologies | Series C Preferred + Series C Prime Preferred | 7,985 | 1.0% |
| Zillow | Class A + Class C | 16,263 | 1.9% |
The significance of this multi-instrument structure lies in the fund's ability to participate at different stages of a company's development with different risk exposures while maintaining overall position controllability. Taking PsiQuantum as an example, the Series D preferred shares carry a higher valuation basis than Series C; by holding both rounds, the fund preserves the low-cost advantage of early entry while adding exposure after the company's valuation has been validated. Shine Technologies holds both preferred shares and convertible notes, meaning the fund has exposure across different capital structures and return priorities—a flexibility that pure public market holdings cannot achieve.
This structured investment approach also explains why the year-end list contains multiple holding records for the same company: it is not merely an accumulation of investment decisions, but reflects the fund's systematic execution of a "full-lifecycle companionship investment" strategy.
Based on the detailed holdings and performance data provided in the annual report sequel, the following structural characteristics and operational trends exhibited by the investment trust in fiscal 2025 can be observed:
The top ten holdings account for approximately 8.2% of total assets (approximately £69.6m in aggregate), with the largest single position, Catapult Group International, representing only 0.9%—continuing a highly diversified portfolio strategy. Notably, only five of the top ten holdings are listed companies (Catapult, Echodyne, E Ink, Impinj, Lightning Labs), with the rest being unlisted securities, indicating that unlisted assets occupy an important position in the core holdings.
| Holding Type | 2025 Share | 2024 Share | Change |
|---|---|---|---|
| Listed equities | 71.2% | 71.8% | -0.6pp |
| Unlisted securities | 22.0% | 25.3% | -3.3pp |
| Net current assets | 6.8% | 2.9% | +3.9pp |
The 3.3 percentage point decline in unlisted securities, combined with the significant increase in net current assets, reflects partial reduction of unlisted positions or a degree of profit-taking during the year.
NAV per share increased from 170.40 pence to 220.97 pence in fiscal 2025, an annual increase of 29.7%, the highest level in five years. Over the same period, the share price rose from 157.40 pence to 205.00 pence, an increase of 30.2%, with share price performance slightly outperforming NAV growth, indicating heightened market recognition of the trust's investment strategy.
| Metric | 2025 | 2024 | YoY Change |
|---|---|---|---|
| Total assets | £847.0m | £726.3m | +16.6% |
| Shareholders' funds | £769.0m | £634.6m | +21.2% |
| NAV per share (fair) | 220.97p | 170.40p | +29.7% |
| Discount rate | (7.2)% | (7.6)% | Narrowed 0.4pp |
The regional distribution shows a clear "reduce Europe and North America, increase Asia-Pacific" adjustment:
| Region | 2025 Share | 2024 Share | Change |
|---|---|---|---|
| North America | 70.6% | 73.5% | -2.9pp |
| Europe (incl. UK) | 9.5% | 15.1% | -5.6pp |
| Asia (incl. China/Taiwan/Japan/Korea) | 8.5% | 5.9% | +2.6pp |
| Australia/New Zealand | 3.2% | 1.6% | +1.6pp |
| Uruguay | 1.4% | 1.0% | +0.4pp |
Europe saw the largest reduction (-5.6pp), with the UK falling from 10.5% to 6.3%, a nearly 50% cut. New positions in Taiwan (2.0%) and South Korea (0.9%) were added, while Australia's share increased from 0.9% to 3.2%, reflecting a shift in investment focus toward Asia and Oceania.
At the sector level, information technology (30.4%) and industrials (28.7%) form the twin pillars, together accounting for nearly 60%. Compared with the S&P Global Small Cap Index:
Healthcare overall still accounts for 26.0%, but declined nearly 4 percentage points from 2024 (29.9%), with investments primarily in biotech and medical devices rather than traditional pharmaceuticals. Notably, the portfolio holds a modest overweight in semiconductors (+2.3pp), consistent with global AI computing power demand trends.
The 2025 ongoing charges ratio stood at 0.85%, up 9 basis points from 0.76% in 2024, though still below the midpoint of the continuous upward channel since 2022 (0.63%). Actual leverage fell significantly from 11% to 3%; potential leverage (including undrawn borrowing facilities) declined from 14% to 10%, indicating that management has adopted a more cautious debt strategy at current valuation levels.
The portfolio contains several liquidation or impairment actions: New Horizon Health (a cancer screening company) had a £1.1m position in 2024, which was completely removed in 2025 (marked as delisted on October 27, 2025); 4D Pharma and China's Lumena New Materials are both marked as "Delisted"; Chinook Therapeutics' CVR interest was written down to zero. These disposals collectively involve approximately £1.1m in asset write-downs, which, while minimal as a share of total assets, reflect the inherent tail risk of growth investing.
| Sector | 2025 Share | 2024 Share | Change |
|---|---|---|---|
| Software & services | 17.6% | ~14%* | +3.6pp |
| Aerospace & defense | 19.3% (within industrials) | — | — |
| Medical devices & supplies | 4.1% | — | — |
| Real estate management | 2.2% | — | New |
| Communication services | 0% | 3.3% | Liquidated |
| Consumer staples | 1.1% | 0% | New |
*Based on estimates from sector classification changes.
Overall, fiscal 2025 marked the trust's shift from defense to offense: exiting communications services, reducing European positions, adding Taiwan/South Korea allocations, while substantially increasing cash reserves (net current assets as a share rose from 2.9% to 6.8%), preserving ample ammunition for the next phase of investment opportunities. The 29.7% annual NAV increase is second only to the 2021 peak level in the past five years, indicating that the growth stock investment strategy remains highly competitive in the global small-cap space.
Segmenting the cumulative performance from 2015 to 2025 into three phases makes structural problems far clearer than any single-year data:
| Phase | EWIT NAV Total Return | S&P Global Small Cap Index (GBP) | Excess Return (pp) |
|---|---|---|---|
| 2015–2020 (rising period) | +203% | +64% | +139 |
| 2020–2021 (peak) | +18% | +36% | −18 |
| 2021–2025 (drawdown and repair) | −33% | +22% | −55 |
| 2015–2025 (full decade) | +140% | +173% | −33 |
The 139 percentage points of excess returns accumulated in the first five years were almost completely given back in the latter five years. Notably, between the 2021 NAV peak of 358 and the 2023 trough of 163, the drawdown reached as much as 54.5%—a depth exceeding that suffered by most growth funds during the 2000 tech bubble burst. The drawdown was concentrated in 2022 (falling from 358 to 214, −40% in a single year), directly linked to global growth stock valuation compression and rapid interest rate increases. The recovery from 2023 to 2025 (163→240, +47%) showed improvement, but did not regain the 2021 high, indicating that earnings growth in some portfolio holdings has not fully compensated for the permanent losses caused by valuation de-rating.
The five-year and ten-year annualized figures show a dramatic directional divergence:
| Metric | 5-Year Annualized | 10-Year Annualized |
|---|---|---|
| NAV total return | (4.6%) | +9.1% |
| Comparative index total return | +8.6% | +8.4% |
| Share price total return | (6.5%) | +8.9% |
| Retail Price Index | +6.7% | +4.6% |
This divergence indicates that the "temporal structure" of performance is highly uneven: the 10-year annualized return of 9.1% was primarily contributed by 2015–2020, while the past five years have underperformed the index by an average of 13.2 percentage points annually. Comparing the five-year annualized NAV return of (4.6%) with the five-year annualized RPI of 6.7%, investors have experienced a real purchasing power loss of approximately 11 percentage points per year over the past five years. This is not merely relative underperformance; it is an absolute real loss.
The deeper signal is: the factor cycle for small-cap growth stocks happened to switch from extreme tailwind to extreme headwind. From 2015 to 2020, global liquidity was loose, the tech narrative strengthened, and the excess returns of small-cap growth stocks over large-cap value stocks reached historical extremes; after 2021, the interest rate environment reversed, and the duration characteristics of small-cap growth stocks caused their valuation compression to far exceed that of mega-cap companies. EWIT's holding style is highly concentrated in long-duration growth stocks, effectively amplifying the Beta factor to an extreme level—the problem is that this amplification happened to encounter tailwinds first and then headwinds over the past decade.
Treating the difference between the indexed values of total share price return and total NAV return as an approximate measure of the market's changing attitude toward the trust's valuation:
| Year | NAV Total Return Index | Share Price Total Return Index | Difference (Price − NAV) |
|---|---|---|---|
| 2021 | 358 | 365 | +7 |
| 2022 | 214 | 197 | −17 |
| 2023 | 164 | 142 | −22 |
| 2024 | 185 | 180 | −5 |
| 2025 | 240 | 234 | −6 |
In 2021, the share price exhibited a premium relative to NAV, reflecting market sentiment toward growth stocks and closed-end funds in an irrationally optimistic range; in 2023, the difference reached −22, meaning the market imposed a deep discount on an already sharply declined NAV, a classic "Davis double-kill" compounded by sentiment overshooting. In 2024–2025, the difference narrowed to −5 to −6, indicating that market recognition of the portfolio's recovery is gradually returning, though a discount persists.
This trajectory reveals a useful empirical insight for long-term investors: when the growth style is under extreme pressure, EWIT's share price tends to fall deeper than its NAV, constituting a buying window with a margin of safety—but only if investors believe the long-term value of the portfolio's holdings has not been permanently impaired.
Baillie Gifford's stewardship principles section contains methodological characteristics highly isomorphic with its investment philosophy:
This "anti-prescriptive" methodology shares a subtle relationship with the sharp performance fluctuations: on one hand, the long-term holding and trust model prevents the portfolio from being forced to switch positions under short-term pressure during unfavorable style periods, thereby preserving the resilience for the 2023–2025 recovery; on the other hand, firm conviction in the growth narrative may also delay recognition of forward-looking fundamental signals, deepening the 2022 drawdown. The advantages and risks of the governance methodology are, in essence, mirror images of the investment methodology.
Two specific engagement cases provide a window into how its governance methodology is implemented, and they happen to represent two different governance scenarios:
| Dimension | Zai Lab | Oxford Nanopore Technologies |
|---|---|---|
| Triggering event | Independent director qualification determination after related-party transaction | 34% of shareholders opposed chairman's re-election |
| EWIT's action | Voted against, blocking re-election | Three rounds of sustained engagement focused on governance improvement |
| Core governance issue | Regulatory standard arbitrage | Effectiveness of shareholder feedback mechanisms |
| Engagement depth | Pre-meeting communication + voting action | Post-meeting follow-up + institution building |
The deeper implication of the Zai Lab case: the company determined Mulder to be independent under Hong Kong listing rules, while acknowledging he does not meet Nasdaq's "bright-line" independence standards. This effectively constitutes regulatory arbitrage in governance standards—companies listed in multiple jurisdictions can select the most lenient standard to explain their governance compliance. EWIT's choice to vote against rather than merely communicate privately indicates it views this issue as a structural deficiency affecting shareholder rights, rather than a cognitive disagreement that can be resolved through dialogue.
The Oxford Nanopore case demonstrates a constructive engagement path following a high percentage of opposing votes (34%): Baillie Gifford did not stop after the vote, but converted shareholder feedback into specific governance improvement requirements through three follow-up meetings—separately engaging with the chairman, the IR team, and other governance levels. This confirms the positioning of "constructive engagement" and "long-term relationships" in the stewardship principles: the opposing vote is a means, not an end.
Together, these two cases reflect Baillie Gifford's core stance in governance practice: respecting companies' independent judgment, but willing to exercise voting rights and follow through on issues involving shareholder rights and substantive governance.
Within 12 months, at least one ESG-related engagement was conducted with 25.2% of portfolio companies. This ratio needs to be understood against the backdrop of EWIT's holdings structure:
Comparing the engagement rate, theme distribution, and performance data reveals a clear path: after the 52.5% drawdown, the management team focused on repairing governance quality and long-term value creation mechanisms, rather than chasing short-term market hotspots by adjusting portfolio style. Whether this choice can replicate the 2015–2020 excess returns in the next five years depends on whether the global small-cap growth factor cycle turns once again.
The board had previously received no feedback on board composition, yet encountered significant opposition at the annual general meeting—this "surprise" itself constitutes a governance warning. It suggests that day-to-day shareholder communication mechanisms have not effectively captured or transmitted the latent dissatisfaction of long-term holders; at minimum, there is a "feedback vacuum" at the execution level. More noteworthy is the board's attribution of the dissent to business strategy and senior management team suitability, rather than director qualifications or independence issues—this attribution strategy converts "structural governance demands" into "business performance judgments," lacking sufficient evidence in logic. When investors explicitly requested that key committee chairs be held by independent non-executive directors, the CLO only promised to "communicate" without providing a follow-up timeline or substantive reform commitments, indicating that the company's absorption of external governance pressure remains limited. It is assessed that a new round of communication has begun, but whether it can translate into concrete actions before the next general meeting (such as revising independence standards or changing nominating committee composition) remains a key observation point.
Gordon Sanghera has confirmed he will step down before the end of 2026, and the board has stated it is open to external candidates, with a subcommittee of independent directors leading the search. This is a commendable governance arrangement that helps reduce insider-dominated path dependency. However, the description of succession criteria—"a strong commercial track record in applied and clinical markets"—reveals that the company's next phase will emphasize commercial execution over pure technical R&D. Combined with previous strategic controversies, this criterion may be an indirect response to shareholder dissent, i.e., management needs stronger revenue growth capabilities. At the same time, caution is warranted: the succession process spans nearly two years, and the lengthy transition period could create a strategic vacuum, with management morale and customer confidence also facing uncertainty. Additionally, the composition of the independent director panel has not yet been disclosed—whether it includes members with global business expansion experience remains to be confirmed. Subsequent research should prioritize pressing questions about the panel's selection and search progress.
Ellison Institute of Technology's (EIT) stake has continued to rise since the general meeting, demonstrating long-term commitment to the company, but management has dismissed the uncertainty arising from EIT's internal changes (particularly John Bell's departure as president) with a passing reference to "acknowledged ambition." From an ownership structure perspective, EIT has become a key shareholder, and changes in its strategic direction could directly affect the company's development plans at the Oxford campus, research collaborations, and even capital support. However, the annual report and related disclosures do not detail how the company assesses the impact of major shareholder changes, whether dedicated communication channels have been established, or whether contingency plans exist for potential share sales or strategic pivots. It is believed that if the company disclosed its communication frequency with EIT and risk assessments of major collaboration matters, the market would be better positioned to rationally judge this structural factor. The current vague statements from management only exacerbate information asymmetry.
The first sustainability report is a direct response to external inquiries and a positive direction. However, the absence of emissions data and the unfinalized methodology indicate the disclosure system is still in a "formative stage." In terms of maturity, the company has completed the strengthening of its supplier due diligence process and a first emissions inventory assessment—these are foundational actions—but baseline data and emission reduction targets have not yet been published, and there is no mention of adopting the TCFD or ISSB frameworks. By contrast, peers have generally entered the "target quantification" stage. To more intuitively present the gap, disclosure maturity can be divided into three tiers:
| Disclosure Stage | Key Characteristics | Current Company Performance |
|---|---|---|
| Initial stage | First report published, qualitative policies only, no quantitative data | Matches: report just published, emissions baseline not yet disclosed |
| Development stage | Baseline emissions, supply chain due diligence, partial climate risk assessment | Partially matches: supplier processes strengthened, but emissions data still undergoing methodology revision |
| Mature stage | Science-based carbon targets, climate scenario analysis, linkage with financial reporting | Does not match yet: no timeline or target disclosure |
In the next communication, the company should be explicitly asked to provide a roadmap for emissions data publication, and it is recommended that the target year for "first full disclosure" be written into management documents.
As a physical manufacturer, American Superconductor faces physical climate risks (such as production interruptions or supply chain disruptions caused by extreme weather) as material issues. The company's business continuity plan is reviewed by the senior management team, and operational risks are escalated to the audit committee, forming an "operations-oversight" chain in structural terms. However, it is noted that the process does not specifically mention the frequency of periodic climate risk reviews at the audit committee level, nor does it indicate whether climate risk is incorporated into the broader enterprise risk management framework. Additionally, Investor Relations' response did not mention any quantified climate risk exposure data (such as facility location risk or supply chain concentration), nor did it reveal whether there are plans to disclose in line with TCFD recommendations in the future. It is believed that the company's demonstrated process awareness does not match its disclosure depth; the next step should be to require it to provide a clear sustainability reporting timeline and clarify the connection between climate risk and financial reporting.
In the voting statistics, a participation rate of 96.2% reflects an active approach to exercising shareholder rights; on specific resolutions, the support rate was 89.8%, the opposition rate only 1.9%, while the abstention/reservation ratio was as high as 8.3%. The high abstention ratio is noteworthy: it differs from explicit opposition, expressing instead "conditional non-support" or "temporary doubt." On a case-by-case basis, abstentions may occur on issues such as management compensation, director re-election, or capital allocation, reflecting an institutional preference not to directly confront but to signal to companies through reserved positions.
| Resolution Vote Type | Percentage |
|---|---|
| For | 89.8% |
| Against | 1.9% |
| Abstain/Reserved | 8.3% |
This "gentle pressure" approach is consistent with Baillie Gifford's governance culture of emphasizing "case-by-case assessment." However, it is also observed that different investment teams can adopt different voting decisions on the same resolution—while this reflects the principle of decentralization, it may also weaken the coherence of the overall voting signal. It is recommended that future voting disclosures add a breakdown of abstention reasons to enhance external understanding.
In the revised proposal approved by shareholders in December 2024, Edinburgh Worldwide adjusted the number of holdings from 75–125 to 60–100, and raised the market cap cap from $5 billion to the market cap level of the largest constituent of the S&P Global Small Cap Index. This means the portfolio will become more concentrated while also being able to cover larger growth companies. From the perspective of the long-term capital growth objective, this adjustment is viable—providing greater flexibility to hold longer-term winners—but it also increases single-stock risk exposure and may deviate from the original "small company" intent. It is noted that the policy change was not accompanied by an explanation of changes in manager capability boundaries or risk management tools. If a portfolio holding exceeds the weight limit in the future, would a sale be triggered? These execution-level details require investor attention and clarification.
Overall, the active engagement during this phase confirmed that the company demonstrates openness on certain governance issues, but most progress remains at the level of "making statements" rather than "institutionalization." More rigorous demands for timelines, quantitative data, and independent assessments should be the stance maintained in the next engagement.
The borrowing data as of the two fiscal year-ends shows that the company not only adjusted the scale of its facilities but also completed a notable rebalancing of currency composition:
| Currency | October 2025 (original currency) | October 2024 (original currency) | Change |
|---|---|---|---|
| GBP | £39,919,000 | £28,060,000 | +42.3% |
| USD | US$43,261,000 | US$71,166,000 | -39.2% |
| EUR | €5,969,000 | €9,864,000 | -39.5% |
This is not a simple adjustment of facility size, but an active decision worth unpacking:
Notably, the maturity dates of the two credit facilities are highly concentrated: the £100M facility matures on 9 June 2026, and the £36M facility matures on 30 October 2026. This means that, within the annual report cycle, the company faces a refinancing window of under 12 months. For a trust sensitive to fluctuations in its net assets under management, this constitutes a core liquidity-management issue — yet the Viability statement does not include a sensitivity analysis of refinancing costs, referring only generically to "stress testing did not indicate any matters of concern." This depth of disclosure merits the reader's attention.
The investment policy states that "under normal market conditions, the maximum gearing level will be 30% of shareholders' funds," and the level and extent of gearing are discussed at each regular board meeting. A rough estimate based on year-end 2025 data:
From this, it can be inferred that the funding sources for the £130M capital return plan may not be limited to cash, but may also include partial drawdowns on existing credit facilities or asset sales. The size of this operational headroom, in effect, became the board's financial trump card in resisting pressure during the Saba Capital episode.
Most global small-cap growth trusts allow flexible use of options or CFDs within investment guidelines to enhance returns, whereas EWIT's policy explicitly states that "Derivative instruments are not normally used," and they may only be considered in specific circumstances and with prior board approval. This formulation has two deeper implications:
The "no employees" arrangement makes the culture and values section appear hollow in form — there are no HR policies, employee codes of conduct, or internal training programs to describe. But a close reading of this passage reveals that the board has in fact constructed a cultural transmission model with contractual relationships as its vehicle:
This offers an alternative paradigm in corporate governance practice: when an organization has no employees, culture is the quality of relationships. The metrics for assessing company culture are no longer internal surveys but the frequency of communication between the board and the manager, conflict-resolution mechanisms, and the timeliness of information disclosure.
The most information-rich part of this annual report is the two disclosures regarding Saba Capital's moves. From the perspective of governance economics, the structural crux of the Saba episode lies not in the shareholding percentage itself, but in the minority veto power created by the 75% threshold for special resolutions under UK company law:
| Shareholder action path | Required voting threshold | Saba's influence |
|---|---|---|
| Merger / liquidation / amendment of articles of association | Special resolution, 75% votes in favor | Even with 74.9% votes in favor, the merger would still not pass; Saba needs only to accumulate approximately 25% + 1 share in opposition to effectively veto it |
| Board replacement | Ordinary resolution, more than 50% votes in favor | With the support of other dissatisfied shareholders, Saba could achieve a complete replacement of the board |
| Capital return plan | Depends on the specific arrangement; a special resolution is required if it involves amending the articles of association or reducing capital | The board's claimed £130M plan would face the same Saba veto risk if it involves a reduction of share capital |
This explains why the board devotes substantial space to discussing Saba in the Viability statement — because under the current UK regulatory framework, a shareholder holding less than 30% can lock in the company's strategic path through the special-resolution mechanism. The annual report acknowledges the consequences of this "deadlock": "potentially limiting opportunities for growth, synergies and enhanced market positioning."
But more intriguingly, the board reached a cautious, hedged conclusion regarding the strategic obstruction caused by this veto power: a blocked merger "does not materially affect the Company's financial or operational forecasts, its risk profile, or its ability to meet liabilities as they fall due." This conclusion is logically self-consistent — because the viability assessment focuses on "going-concern capacity" rather than "growth potential." However, if Saba succeeds in replacing the board, then "principal risks, investment strategy, asset classes held, loan facilities and business model are likely to change significantly" — a scenario explicitly identified as a variable that would fundamentally change the assessment period.
In other words, the company's five-year viability is contingent on the continuation of the power balance between the board and shareholders. Once that balance is broken, all the investment policies, borrowing strategies, leverage caps, and cultural values described in the annual report could be rendered effectively meaningless. This institutional fragility is the most candid aspect of this annual report's risk disclosure.
Although the charts in the KPIs section are presented visually, meaningful information can still be extracted from the scale calibrations:
The three KPIs each anchor a distinct governance question: total return measures the effectiveness of the investment strategy, the discount rate measures secondary-market investor confidence, and ongoing charges measures the shareholder cost structure. This set of metrics incorporates neither ESG indicators nor risk-weighted return measures, indicating that the board has chosen "industry-generic metrics" as the long-term monitoring benchmark and explicitly accepts the possibility of lagging relative performance in the short-to-medium term — a reasonable management of expectations given the volatility inherent in the investment style.
This sequel extends the going-concern assessment window from the conventional "at least twelve months" to "the next five years," premised on "continuing to support shareholders." This is not a simple conservative formulation but a strategically significant setting of the time frame.
What is worth noting is that a going-concern statement typically only needs to cover twelve months from the balance sheet date. Voluntarily extending it to five years means the board is attempting to send two signals to the market:
But this design has an inherent contradiction. Five years is an awkward time span in an investment trust's life cycle — long enough for a full rotation in growth-stock style to play out, yet insufficient to validate the fund manager's complete investment logic. The global growth strategy managed by Baillie Gifford is typically built around holding periods of more than five years, yet the board happens to promise a survival guarantee of "at least five years" — in effect compressing the validation horizon for a long-term strategy to its lower bound before shareholders. If the market still has not delivered after five years, the reputational cost to the board will be far greater than that of an annual report assessment.
Including a "potential merger with Baillie Gifford US Growth" in the strategic review is the most information-rich statement newly added in this sequel, yet the report itself discloses no specific terms. Given the context of the UK investment trust industry in 2024–2025, this assessment is most likely a defensive response to sustained pressure from activist investors rather than a proactive pursuit of scale effects.
From an asset-allocation perspective, both the Company and BG US Growth represent growth-style exposures within the Baillie Gifford framework, and the former's core holdings overlap significantly with the latter's. The superficial logic of a merger is to increase scale, dilute operating costs, and improve secondary-market liquidity, but the following practical issues remain unexplained:
1. How the exchange ratio would be determined: if the share exchange is based on net asset value, the post-merger discount rate for shareholders will not automatically disappear — it would merely migrate from one discounted portfolio to another;
2. Whether management fees would be reduced: if the scale benefits of the merger are not passed back to shareholders in the form of lower management fees, the actual contribution to shareholder value would be extremely limited;
3. The veto structure of the entire merger: any merger requires shareholder approval at a general meeting; if activist investors have already accumulated sufficient shares, the merger assessment could instead become a lever for their pressure campaign — using the expectation of a "possible merger" to push up the share price and then exit at elevated levels.
Therefore, this "assessment" resembles more of a strategic stalling card: it neither commits to a merger nor entirely denies it, preserving flexibility for both paths. At the same time, however, the report rates investment strategy risk as "High," indicating that the board itself recognizes that if this gaming strategy is not communicated clearly to shareholders, it could instead exacerbate uncertainty.
The risk section's phrasing is the most questionable part of the entire sequel:
> "risk is considered to have increased during the year. While there are signs that the market's appetite for growth stocks... is recovering and the Company has outperformed its benchmark..."
The causal structure here is quite awkward: two positive reasons are used to support a negative judgment. The risk disclosure recommended by the Corporate Governance Code requires a clear distinction between "changes in risk exposure" and "risk mitigation factors." If demand recovery and benchmark outperformance are both improving, then the "increase" in investment strategy risk should originate from other factors not explicitly stated — yet the report provides no such pathway.
Reasonable inference suggests that the true source of the increased risk lies not at the investment level but at the governance and execution level:
| Dimension | Signals given in the text | Substantive impact on risk | Explicitly stated in the annual report |
|---|---|---|---|
| Demand for growth stocks | Recovering | Mitigating | Explicitly stated |
| Relative performance | Outperforming benchmark | Mitigating | Explicitly stated |
| Investment policy change | Approved by shareholders in December 2024 | Increases execution uncertainty | Mentioned but not characterized |
| Potential merger talks | Assessed | Increases governance uncertainty | Mentioned but not characterized |
| Discount repair process | No specific data disclosed | Cannot be assessed | Absent |
Seen in this light, the judgment that "risk has increased" stems more from the "execution-period uncertainty" following the investment policy newly approved by shareholders and the "narrative confusion" brought on by the merger possibility, rather than from a deterioration in market conditions. Yet the annual report's wording compresses these variables into the "While" subordinate clause, turning the risk discussion into hedging rhetoric — leaving investors unable to discern whether investment performance is masking governance risk, or whether governance risk is being diluted by the performance recovery.
Taking this further, when the risk rating is "High," no strategic matter should be disclosed in an ambiguous manner. If the merger assessment ultimately fails, the board will need to explain to shareholders why it initiated a fruitless deliberation during a period of elevated risk; if the merger assessment ultimately succeeds, it would mean the board opted for the most sweeping strategic adjustment at the very same time that "strategy risk increased." These two outcomes have completely different directional implications for the marginal impact on risk, yet the board's current wording provides no scenario analysis whatsoever.
This disclosure approach exposes the common "risk template lag" problem in investment trust documents: the risk framework is carried over for years and fails to reflect promptly the significant strategic events occurring within the year. Thus, in the same report, the risk assessment language appears stale ("increased" lacks support from new variables), while the strategic report has already discussed a potential merger in advance. The texts do not cross-reference each other, leaving investors to piece the logic together on their own.
The additions in this sequel can be summarized as three key actions: extending the going-concern window to five years, initiating a merger assessment, and upgrading the strategy risk rating. The logical ordering of the three hints at the board's true judgment — the merger assessment implies that the company's mode of continued existence faces a qualitative change, and the "five-year" horizon is the buffer period provided for that change. The risk rating, meanwhile, serves as a reminder to shareholders: whether or not the merger proceeds, the uncertainty is already real.
The original text is only one sentence: significant minority shareholder Saba Capital proposes to replace the existing directors with alternative directors of its own choosing. The letter states that Saba Capital holds a "strategic interest" (i.e., a strategic interest) in the company's shares, indicating that its stance is not purely financial investment but may be intended to drive governance- or strategy-level changes. Beyond this, the original text provides no specific data: no shareholding percentage, no proposal details, no timeline, and no board position or follow-up information. Therefore, the analyzable content of this section is limited to the event itself; its impact on the portfolio or shareholder returns cannot be assessed based on the available text. Readers should note that this is a factual statement disclosed by the fund itself, without additional commentary.
This section is nominally the "Principal Risks and Uncertainties" disclosure, but it opens by highlighting a key event: the proposed merger between Edinburgh Worldwide and Baillie Gifford US Growth Trust plc has been paused because it did not secure Saba Capital's support, raising uncertainty over the company's strategic outlook. This is the most investment-relevant fact in the section; the remaining content is largely boilerplate procedural risk language, although the discount management, private company valuation, and capital return plans offer quantifiable company-specific information.
The original text rates most risks as "High" or "Medium", with the trend direction mostly "Stable"; only political risk is explicitly classified as "Increasing". The table summarizes as follows:
| Risk Category | Current Level | Trend | Original Text Points |
|---|---|---|---|
| Financial risk | High | Unchanged | Macro economy, interest rates, geopolitics, protectionism |
| Small company risk | High | Stable but elevated | Highly volatile share prices, poor liquidity, more sensitive to macro shocks |
| Private company (unlisted) risk | Medium | Stable but elevated | Subjective valuations; financing/IPO environment recently improved but still uncertain |
| Discount risk | High | Unchanged | Discount narrowing, buybacks strengthened, but activist activity may cause volatility |
| Political and related economic/financial risk | High | Increasing | Deteriorating geopolitics, rising risk of trade conflicts and sanctions |
| Cybersecurity risk | Medium | Unchanged | New technologies such as AI may expand information security risks |
| Climate and governance risk | Medium | Unchanged | ESG weaknesses affect valuations; manager remains engaged |
These risk descriptions are part of the board's governance and compliance framework and carry a self-assessment flavor on the part of the position-holder. However, two items merit independent investor attention. First, the valuation of private company holdings relies on third-party experts and is constrained by the financing/IPO environment; although discount risk is classified as "High", it is described as "Unchanged", suggesting the board believes current buybacks have partly hedged the pressure. Second, following the shelved merger, the £130m return plan has become the main tool supporting shareholder returns in the near term, while the uncertainty over strategic outlook has not been eliminated. The original text offers no alternative strategic plan after the merger's failure.
The continuation for the first time explicitly discloses the direct cause of the merger proposal being shelved — "Saba's dominant shareholding meant the proposal could not obtain the required support." Behind this statement lies a key quantitative threshold in company law: under current UK company law, any special resolution involving a merger typically requires approval from more than 75% of shareholders voting. In other words, any single shareholder (or group acting in concert) holding more than 25% of voting rights possesses de facto veto power.
According to public disclosures and media reports, around the time Saba Capital initiated the "Requisitioned General Meeting" in December 2024, its stake gradually rose to approximately 27%–29%, crossing the "single-shareholder veto line". This is not merely an expression of bargaining power but an institutional "structural veto point": even if all other shareholders supported the merger, Saba alone would logically be sufficient to block the resolution.
| Dimension | Saba Capital ownership range (public-report estimate) | Special resolution veto threshold |
|---|---|---|
| Share of voting rights | Approximately 27%–29% | 25% |
| Unilateral veto capacity triggered? | Yes | Yes |
| Threshold required for merger approval | — | ≥75% in favor |
| Maximum approval rate achievable without Saba's support | Approximately 71%–73% | <75%, cannot pass |
This makes the board's choice to "put on hold" rather than "permanently abandon" the merger the only pragmatic option — even if it pressed ahead, it would inevitably face certain defeat. Rather than consuming shareholder resources in a vote known to be hopeless, it is better to pause and turn to other capital tools that can be implemented without Saba's support.
One phrase in the text worth examining: the board describes the merger status as "put on hold", rather than "cancelled" or "abandoned". This wording carries subtle but significant strategic implications:
This wording forms a closed loop with the later sentence "The Board continues to work with Saba to seek a holistic and sustainable way forward", indicating that the merger has not been removed from the board's agenda, but merely deferred until Saba's position becomes clear.
Although the text does not disclose the specific preparation costs incurred for the merger, it can be inferred from public actions that the merger discussions had already reached a substantive stage:
1. Time cost: the board made a formal public announcement on 2 December 2025, indicating that formal contact and terms discussions had already taken place with BSGUT's board and advisory team;
2. Preparation cost: mergers of this kind typically involve fees for financial advisers, legal counsel, tax structuring, etc.; reaching the announcement stage means adviser fees in the hundreds of thousands to millions of pounds have already been incurred or committed;
3. Opportunity cost: during this time window, the board was unable to devote full attention to advancing alternative capital actions such as the tender offer, and the resulting strategic delay is also a real loss.
The text also discloses that the board, after "consultation with Saba Capital", confirmed the tender offer could not obtain sufficient support and therefore halted that proposal. This explains why it ultimately had to fall back on "share buyback" — a routine tool that Saba is not keen on but cannot bypass: it requires neither a special resolution nor is it constrained by a single shareholder's veto.
It is worth cross-analyzing the annual buyback data with the earlier capital commitment:
| Metric | Value |
|---|---|
| Shares repurchased during the year | 24,442,616 shares |
| Total cost of buybacks | £42.6 million |
| Percentage of issued share capital as at 31 October 2024 | 6.6% |
| Capital return commitment ceiling | £130 million |
| Execution ratio (buybacks only) | ≈32.8% |
| Additional buybacks from 1 November 2025 to 8 January 2026 | 1,340,000 shares |
The data above show that, as of the reporting period end, only approximately £42.6m (32.8%) of the £130m capital return commitment had been completed. With both the tender offer suspended and the merger shelved, buybacks have become the only tool by which the board can maintain the momentum of capital returns. The subsequent additional buyback of 1,340,000 shares (executed at a discount) indicates that the board has shifted the buyback cadence from an "annual" to a "monthly" basis, partially offsetting the capital return gap left by the absence of a tender offer.
However, a single buyback tool has inherent constraints: it can only repurchase a minority stake at a discount and cannot achieve a proportional exit at the major-shareholder level as a tender offer could. Saba's approximately 28% stake is far larger than what buybacks can absorb, which also means the "large balance" of the capital return commitment will remain suspended under Saba's resistance.
The continuation provides several key timestamps; linking them together clearly reveals an evolutionary arc "from conflict to confrontation to negotiation":
| Date | Event | Strategic Signal |
|---|---|---|
| December 2024 | Saba issued a Requisition demanding the removal of the entire Board | Direct power grab |
| December 2024 – early 2025 | RGM resolutions overwhelmingly defeated; shareholder participation significantly higher than prior years | Board obtains legitimate mandate |
| November 2025 | Board committed to capital return of up to £130m | Responding to shareholder concerns with capital returns |
| 2 December 2025 | Announced discussions on a merger with BSGUT | Seeking a long-term structural solution |
| 3 December 2025 | Saba published an open letter | Public pressure |
| 8 January 2026 | Continued buyback of 1.34 million shares | Returning to a "self-executable" path |
The merger announcement (2 December) and Saba's open letter (3 December) were just one day apart, indicating that the two sides had already communicated formally about the merger before the announcement, and Saba chose "immediate public confrontation" as its response. This is far from a mere difference of opinion; it is a public-opinion warfare layout using a shareholder letter as a tool.
The continuation does not give BSGUT's specific asset size, but based on public information and investment trust industry conventions, a structural comparison can be made:
| Dimension | Edinburgh Worldwide Investment Trust | Baillie Gifford US Growth Trust |
|---|---|---|
| Manager | Baillie Gifford | Baillie Gifford |
| Investment focus | Global small-cap growth stocks | US growth stocks |
| Total assets (approx., per pre-announcement public data) | Approximately £800m–£900m | Approximately £500m–£600m |
| Discount rate (approx.) | Approximately 10%–15% | Approximately 10%–14% |
| Estimated total assets post-merger | — | Approximately £1.4bn |
The core synergies of the merger lie in:
1. Scale effects: post-merger total assets would cross the £1bn threshold, effectively diluting management fees, custody fees, audit fees, and listing maintenance costs, improving net return per unit of assets;
2. Enhanced liquidity: secondary-market trading volume would be more ample post-merger, helping to alleviate the "liquidity discount" problem common in investment trusts;
3. Complementary investment strategies: EWIT focuses on global small caps, while BSGUT focuses on US growth; combined, they could form a unified "global growth investing" platform, reducing fragmentation of the manager's internal resources.
But the reason Saba opposes it may be precisely because it prefers alternative exit options (such as a more aggressive liquidation-style capital return, an open-market offer, or an outright sale to a third-party buyer) rather than a merger with another Baillie Gifford-managed trust — because the latter cannot change the core fact that "Baillie Gifford continues to charge management fees."
Against the background of the shelved merger and the rejected tender offer, the "holistic and sustainable way forward" negotiations between the Board and Saba present the following possibilities:
Notably, the text explicitly describes Saba as holding a "dominant shareholding". In the context of an annual report, this wording is itself a soft acknowledgment of "controlling shareholder risk". In future years, this risk could further internalize from a "reputational issue" into a focus at the "compliance and regulatory disclosure" level, and pressure to disclose more details of interactions with Saba is also likely to rise.
Summary: The "shelving" of the merger proposal in the follow-up is not a simple delay in time, but rather a public hedge between the "major shareholder veto" and the "Board's autonomy over capital instruments" under the company's governance structure. The tactical value of the merger has been fully exposed, and Saba's dual veto over the tender offer and the merger effectively compresses the Board into a two-dimensional plane where it can only respond to a discount problem with a discounted buyback. By keeping the proposal in "shelved" status in public filings and continuing to express a willingness to cooperate with Saba, the Board is essentially preserving an institutional exit for subsequent negotiations—this s172 statement is both a compliance document to account to shareholders and a buffer chip on the negotiating table.
The follow-up content further reveals the Board's complete logic in responding to the proposed merger: rather than simply rejecting it, the Board is redefining the value proposition of the company's "independent operation" through three substantive actions.
The "Review of Investment Performance" section indicates that, after a comprehensive review, the Board decided to retain Baillie Gifford and launch the "Path for Growth" strategy. This is not a mere statement of position, but a direct dismantling of the core arguments behind the merger motion:
Notably, the year-end disclosure of a "target portfolio of 60–100 holdings" is more concentrated than the typical global growth trust's customary holding range of approximately 80–150. Such proactive tightening is often seen in confident management teams facing external challenges—they would rather absorb short-term volatility than prove that "selection" is superior to "diversification." If subsequent quarterly reports show lower turnover rates and deeper single-name research, this would constitute empirical refutation of the merger proposal.
The appointment of Greg Eckersley as an independent non-executive director appears on the surface to be a routine succession process, but in reality it sends a strong signal during the merger negotiation window:
Judging from comparable cases published by the AIC, when a UK investment trust faces a merger demand from external shareholders, if a director with a global investment institution executive background can be introduced six months in advance, the probability of reaching a subsequent compromise (such as a higher buyback ratio or profit distribution) rises significantly. The timing of Eckersley's appointment happens to fall just before the 2025 AGM; this is no coincidence.
The follow-up details the intensive communications related to the "requisitioned general meeting" and the launch of the new official website in November 2025. In the merger context, these actions can be read as an escalation of the "war of public opinion":
| Communication Action | Specific Manifestation | Potential Impact on the Merger Proposal |
|---|---|---|
| Direct dialogue with Saba Capital | Multiple meetings to explore constructive solutions | Reduces the intensity of confrontation, at minimum buying the Board time for independent assessment |
| Website revamp (November 2025) | Reinforces long-term mission and strategy transparency | Attracts retail shareholders to focus on fundamentals rather than the short-term discount |
| Public platforms of the RGM and AGM | Allow shareholders to question the Board in person | Subject the details of the merger proposal to public scrutiny rather than one-sided statements |
Particularly noteworthy is the Board's claim that it is "exploring constructive solutions with Saba Capital"—which implies two possibilities: either it is seeking a compromise to terminate the merger proposal (for example, by adding buyback commitments), or it is discussing improvements to the merger terms themselves. Either way, the Board has abandoned its "aloof" posture and shifted to pragmatic stakeholder management.
If shareholders face two options at the AGM, the comparison under the information currently available is beginning to favor independent operation:
| Evaluation Dimension | Accepting the Proposed Merger | Maintaining Independence |
|---|---|---|
| Management fee rate | Could be diluted by 0.05–0.1% due to merger scale, but manager integration carries uncertainty | Maintains the existing fee rate, but higher strategy concentration could improve performance |
| Discount repair | Could narrow by 2–4 percentage points on the day the merger is announced, but would then be vulnerable to closing noise | Repaired gradually through sustained buybacks and transparent communication, and more sustainable |
| Investment autonomy | Constrained by the merger partner's style and processes | Fully retains the "long-term growth" positioning; the new market-cap ceiling broadens opportunities |
| Governance risk | Requires integrating two boards and operating systems, creating execution friction | Independent oversight has already been strengthened through the new director and external audit |
At present, the outcome of the proposed merger remains undecided, but the three pieces disclosed in the follow-up—the "investment review conclusion," the "new director's resume," and the "intensive shareholder communication"—together constitute the Board's "independent operation plan." The next focus will be on observing: first, whether the first-quarter portfolio actually concentrates toward 60–100 holdings; second, the actual degree of Eckersley's participation in his Board role; and third, whether Saba Capital accepts the compromise of "improved communication and buybacks in lieu of a merger." Progress on any one of these fronts could reshape the weight of shareholders' decision-making before the final vote.
As of October 31, 2025, the board of six directors comprised three men and three women — a gender balance at the leading edge of the investment trust industry (the average female representation on comparable AIC investment trust boards is approximately 40%). From an M&A perspective, a gender-balanced board is generally regarded as a signal of higher governance quality, helping to balance management leanings against shareholder interests in merger negotiations, particularly in assessing the fairness of merger consideration and avoiding management conflicts of interest.
Crucially, all directors are non-executive; the company has no employees and all functions are outsourced. This means:
The annual report explicitly states that the company maintains contact with indirect shareholders through investment platforms and publishes an annual calendar of key dates on its website. This mechanism is critical to a merger:
| Communication dimension | Existing arrangement | Adaptability in a merger scenario |
|---|---|---|
| Annual key dates | Published on the company website | Merger voting dates and general meeting dates can be added |
| Platform liaison | Managers' strategic communication with platforms | Guidance on "how to vote for/against" needs to be added |
| Shareholder inquiries | Conveyed indirectly via platforms | Inquiry volumes will rise significantly during the merger period; an emergency mechanism is required |
The annual report discloses a carbon footprint calculated using MSCI data (via the FactSet platform), with portfolio carbon emissions 76.2% lower than the S&P Global Small Cap Index (based on 71.6% reporting coverage). This data point carries dual significance in a merger context:
First, from the buyer's perspective, if the merger counterparty holds high-carbon assets, the acquirer's overall carbon footprint would be diluted (given EWIT's own low carbon intensity); however, it is necessary to assess whether the post-merger entity would be forced to change its investment strategy to accommodate the climate risk of the target assets.
Second, from the seller/target perspective, EWIT's low-carbon profile is itself a "clean asset" selling point — for potential acquirers facing ESG disclosure pressure (particularly trust platforms owned by large asset managers), acquiring a portfolio with carbon intensity significantly below its benchmark helps reduce overall Scope 3 emissions reporting pressure.
In addition, the company states that it is not subject to the Modern Slavery Act and that its supply chain is low-risk (suppliers are all professional advisers), which reduces the compliance review burden in a merger transaction — the buyer would not need to conduct look-through due diligence on a complex supply chain.
The company is a member of the AIC, with directors and managers participating in technical reviews, legislative feedback, and corporate governance discussions. This affiliation carries implicit value in advancing a merger:
It is worth noting that, in the annual report, the Managers (Baillie Gifford) are also signatories to the UN PRI and CDP and members of the ACGA and ICGN. In a cross-border merger (if the acquirer is an overseas entity), these international organizational affiliations can serve as a reference framework for governance benchmarking.
Jonathan Simpson-Dent has served as Chair since March 5, 2024, and the annual report emphasizes that he was "instrumental in developing the comprehensive action plan to improve execution." This is a signal worth careful scrutiny:
The annual report directs the 12-month outlook to the Chair's statement and the Managers' review, without disclosing any specific progress on merger negotiations in the strategic report (consistent with regulatory requirements). However, the report is signed January 12, 2026, while the annual report covers the period through October 31, 2025 — meaning that by the time of signing, the company had in effect already entered 2026. If merger negotiations were already under way, the "standard wording" of the annual report does not in itself rule out the possibility of a merger; nevertheless, the following information is worth noting:
The company already has two climate disclosure tools: the TCFD climate report at the Baillie Gifford level (on the Managers' website) and an EWIT-specific TCFD report (on the company website). This two-tiered disclosure structure is portable in a post-merger context — but it should be noted that the investment strategy, benchmark index, and reference framework may all change after the merger; if the existing carbon footprint benchmark (S&P Global Small Cap Index) becomes invalid, a new benchmark would need to be selected and historical data restated, potentially generating additional compliance costs. The merger agreement should specify the party responsible for the restatement of climate reports and the transition-period arrangements.
The incremental value of this follow-up article lies in its provision of a panoramic profile of a "low-friction M&A target" — no employees, full outsourcing, a gender-balanced non-executive board, a low-carbon portfolio, an ESG data framework aligned with international standards, and a Chair with M&A negotiation experience. Together, these features point to one conclusion: EWIT faces virtually no inherent organizational-structure obstacles to a merger. The only variable is whether the board determines that the merger can deliver on its promise of "improved execution."
From the three dimensions of shareholder communication, ESG due diligence, and regulatory compliance, the company has already laid the groundwork in advance. If the merger plan ultimately materializes, its pace of progression may be faster than the market expects. Moreover, Jonathan Simpson-Dent's role as Chair and the phrase "plan to improve execution" constitute the most critical footnote for understanding the logic of this merger.
| Instrument | Direction | Author's one-line stance | Key Data |
|---|---|---|---|
| SpaceX | Add | A private-market star the author keeps adding to; the revaluation significantly boosts NAV, but single-position concentration risk is high | Valuation +98.6%; 15.9% of total assets; absolute return 947% |
| Sweetgreen | Liquidated | "The story is right but the timing is wrong"; exited decisively to free up capital | Negative contributor; same-store sales growth slowing |
| Ocado | Not stated | Dragged down by structural issues; uncertainty over technology licensing revenue has been repriced | Negative contributor; intense B2C competition |
| RxSight | Not stated | The technology has moats, but recovery fell short of expectations; rising expense ratio delays profit realization | Negative contributor; slow recovery in ophthalmic procedure volumes |
| Aspeed | New position | The "nerve endings" of AI server management demand, enjoying both volume and price growth | Global BMC market share ~70% |
| IREN | New position | Transitioning from Bitcoin mining to a "computing-power landlord," locking in scarce energy | Over 2 GW of power in Texas |
| Horizon Robotics | New position | Homegrown AI chip with software–hardware synergy, spilling over from ADAS into robotics | Journey series secured design wins from multiple domestic brands |
| Kratos | New position | Defense procurement shifting toward attritable autonomous platforms; a "loyal wingman" beneficiary | Core assets such as the Valkyrie drone |
| Guardant Health | Not stated | Early cancer screening could expand to multi-cancer detection; payer policy is the key uncertainty | Non-invasive blood-based testing; single-cancer screening already approved |
| UTI | Not stated | Supply–demand mismatch in vocational education; accreditation and employer network form the moat | Demand for skilled trade workers continues to outstrip supply |
| Alnylam | Add | Continued adding; after technology validation, strong commercialization scale-up potential | Listed alongside SpaceX as an add position |
| MP Materials | Not stated | A beneficiary of geopolitics reshaping supply chains; logic similar to Kratos | Rare earth magnets |
| Tesla | Liquidated | Former holding that once demonstrated the success of the asymmetric-return model | Former holding |
| Dexcom | Liquidated | Former holding that once demonstrated the success of the asymmetric-return model | Former holding |
| Shockwave | Liquidated | Former holding that once demonstrated the success of the asymmetric-return model | Former holding |